Filing Flows › ImmunityBio (IBRX) › Q3 2026 › vs Q2 2026
ImmunityBio (IBRX) Q3 2026 vs Q2 2026 (quarter over quarter)
ImmunityBio's revenue fell $2.4M (-5%) from $51.2M in Q2 2026 to $48.8M in Q3 2026.
ImmunityBio, Q3 2026: revenue $48.8M (+52% year over year), operating margin -159.7%, net loss $185M, operating cash flow −$75.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $48.8M | $51.2M | −$2.4M | -5% |
| Net loss | $185M | $230M | −$45.8M | -20% |
| Costs & expenses | $233M | $282M | −$48.2M | -17% |
| Operating costs | $127M | $113M | $13.9M | +12% |
| Interest & other, net | $107M | $169M | −$62.1M | -37% |
| Cost of revenue | $1.3M | $298K | $993K | +333% |
| Other operating costs | $126M | $113M | $12.9M | +11% |
| Operating cash sources | $185M | $230M | −$45.8M | -20% |
| Depreciation & amortization | $3.9M | $4.4M | −$518K | -12% |
| Share-based compensation | $8.7M | $8.5M | $198K | +2% |
| Working capital & other | $96.6M | $151M | −$54.3M | -36% |
| Cash used in operations | $75.3M | $66.5M | $8.8M | +13% |
| Net loss absorbed | $185M | $230M | −$45.8M | -20% |
Questions
How much did ImmunityBio's revenue grow quarter over quarter in Q3 2026?
ImmunityBio's revenue fell $2.4M (-5%) from $51.2M in Q2 2026 to $48.8M in Q3 2026.